子宮頸部異形成としても知られる子宮頸部上皮内腫瘍（CIN）は、子宮頸部の表面に細胞が異常に出現することを特徴としています。子宮頸部異形成は通常、25 歳から 35 歳の女性に発生します。子宮頸部異形成のほとんどの症例は、ヒトパピローマウイルス（HPV）によって引き起こされます。子宮頸部異形成に寄与する要因には、免疫抑制薬の使用と喫煙が含まれます。兆候と症状には、性器疣贅、異常出血、性交後の出血、おりもの、腰痛などがあります。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
Featured News & Press Releases
Mar 08, 2022: Nykode Therapeutics to present at 2022 American Association for Cancer Research (AACR) Annual Meeting
Dec 14, 2021: INOVIO highlights key updates on phase 3 program for VGX-3100, its DNA-based immunotherapy for the treatment of cervical HSIL caused by HPV-16 and/or HPV-18
Apr 21, 2021: Antiva Biosciences appoints Clifford Samuel to Board of Directors
Mar 26, 2021: The VGX-3100 project of Dongfanglue passed the approval of the Genetics Office, and officially launched the domestic phase III clinical trial
Feb 20, 2020: Novan receives phase 2 NIH federal grant of approximately $1.0 million
Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event
Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019
Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting
Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data
Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial
Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer
Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene' TG4001
May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100
Apr 17, 2019: Inovio's phase 3 HPV immunotherapy selected as "Best Therapeutic Vaccine" at World Vaccine Congress
Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, 2022
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, 2022 (Contd..1)
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
